BMRA
BIOMERICA INC
$2.12
-1.40%
$6.6M
No data for this timeframe.
Vol
Market Cap$6.6M
Cap SizeNano Cap
Inst. Holders2 funds
Inst. Value$53.4K
Inst. Activity0 buys / 1 sells
SEC Reports2
Press Releases2
Exchange Nasdaq·Sector In Vitro & In Vivo Diagnostic Substances·Inc. DE·CIK 0000073290·Prev Close $2.15
Recent Activity
Jun 4, 2026
SEC
Biomerica entered into a Securities Purchase Agreement to sell its 6% stake (78,750 shares) in Diagnosis S.A. to buyers
8-K — Impact 4/10
Apr 13, 2026
SEC
Biomerica reported Q3 fiscal 2026 results with revenue down 11.6% YoY to $987K, driven by lower contract manufacturing,
PRESS-RELEASE — Impact 6/10
Inst.
UBS Group AG — NEAR_EXIT
115 shares ($325.00)
Inst.
VANGUARD GROUP INC — NEW
21,127 shares ($66.8K)
May 28, 2026
Press
Biomerica entered a Master Services Agreement with a confidential life sciences company to develop proprietary IVD assay
Impact 6/10
May 28, 2026
contract
Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
Auto-renewing Master Services Agreement engages Biomerica’s integrated development and manufacturing
Apr 14, 2026
Press
Biomerica announced the commercial launch of its inFoods® IBS diagnostic-guided therapy in Canada through partnerships w
Impact 6/10
Analyst Ratings
3Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 19, 2020 | Aegis Capital | MAINTAIN | Buy |
| Sep 4, 2020 | Aegis Capital | MAINTAIN | Buy |
| Aug 21, 2020 | Aegis Capital | INITIATE | Buy |
| Dec 17, 2018 | B. Riley Securities | MAINTAIN | Buy → Buy |
Latest Reports
NEUTRAL
8-K
4/10
Biomerica entered into a Securities Purchase Agreement to sell its 6% stake (78,750 shares) in Diagnosis S.A. to buyers
Jun 4, 2026
BULLISH
Press
6/10
Biomerica entered a Master Services Agreement with a confidential life sciences company to develop proprietary IVD assay
May 28, 2026
MIXED
PRESS-RELEASE
6/10
Biomerica reported Q3 fiscal 2026 results with revenue down 11.6% YoY to $987K, driven by lower contract manufacturing,
Apr 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $53.2K | NEW |
| BANK OF AMERICA CORP | $124.00 | — |
2 institutional holders with $53.4K total value (21,176 shares) as of 2025-Q4. Top holders: VANGUARD, BANK.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 21,127 | $53.2K | 99.8% | NEW |
| 2 | BANK OF AMERICA CORP /DE/ | 49 | $124.00 | 0.2% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | NEAR_EXIT | 549 | 115 | -79.1% | $325.00 | 2025-Q3 |
| VANGUARD GROUP INC | NEW | — | 21,127 | — | $66.8K | 2025-Q2 |
| VANGUARD GROUP INC | EXIT | 169,010 | 0 | -100.0% | $0.00 | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 42,362 | 0 | -100.0% | $0.00 | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 42,362 | — | $24.0K | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 23,300 | 36,100 | +54.9% | $20.5K | 2025-Q1 |
| UBS Group AG | TRIM | 23,253 | 16,288 | -30.0% | $9.2K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 53,700 | 23,300 | -56.6% | $7.0K | 2024-Q4 |
| UBS Group AG | TRIM | 91,692 | 23,253 | -74.6% | $7.0K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 565 | 315 | -44.2% | $103.00 | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 5.0/10.
Historical analyst distribution (last covering-analyst action Oct 2020): 86% buy across 7 analysts — 3 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2022-05-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Oct 19, 2020 | Aegis Capital | MAINTAIN | — | Buy |
| Sep 4, 2020 | Aegis Capital | MAINTAIN | — | Buy |
| Aug 21, 2020 | Aegis Capital | INITIATE | — | Buy |
| Dec 17, 2018 | B. Riley Securities | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jul 1, 2022 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Jun 1, 2022 | 3 | 3 | 1 | 0 | 0 | 86% | |
| May 1, 2022 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Apr 1, 2022 | 3 | 3 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 28, 2026
contract
Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
Auto-renewing Master Services Agreement engages Biomerica’s integrated development and manufacturing platform, reflecting the Company’s CDMO strategy
Apr 29, 2026
other
Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
Real-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented at the world’s largest GI medical conference, May
Apr 16, 2026
other
Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
Company and Laboratory Partner Believe Properly Documented Claims Are Positioned for Payment Under Existing $300 CMS Reimbursement Rate <pre>Company a
Apr 14, 2026
contract
Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
<p><em>— Represents Biomerica’s First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy </em><br><em>— Canada Has
Apr 13, 2026
earnings
Biomerica Reports Third Quarter Fiscal 2026 Financial Results
<p>IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or the “Company”) a global provider of advanced m
Apr 13, 2026
earnings_calendar
BMRA Q3 2026 Earnings Scheduled — 2026-04-13
Mar 18, 2026
other
Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe
<p>IRVINE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeut
Mar 5, 2026
other
Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain
Registration marks the Company’s entry into the UK market, where H. pylori affects an estimated 45% of the population across Europe’s five largest cou